Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study

Longeveron Inc announced topline results from the Phase 2a trial of its investigational product Lomecel-B for mild Alzheimer's disease.

An estimated 6.7 million Americans are living with Alzheimer's disease. Of the total U.S. population, about 1 in 9 people aged 65 and older has Alzheimer's disease.